As of Apr 20
| +0.28 / +3.46%|
The 1 analysts offering 12-month price forecasts for Clinuvel Pharmaceuticals Ltd have a median target of 25.66, with a high estimate of 25.66 and a low estimate of 25.66. The median estimate represents a +206.16% increase from the last price of 8.38.
The current consensus among 1 polled investment analysts is to Buy stock in Clinuvel Pharmaceuticals Ltd. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.